IP Library Granted Patent US 12,474,321
Granted Patent B2
US 12,474,321 · App. 16/990,602 · Granted Nov 18, 2025

Nanopore protein conjugates for detection and analysis of analytes

Inventors: Mark R. Ambroso (San Diego, CA); Kapil M.S. Bajaj (Newark, CA); Timothy K. Craig (Campbell, CA)
Assignee: Roche Diagnostics Operations, Inc.
G01N33/48721C07K14/31G01N33/54306C07K2319/40C07K2319/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,474,321
App. No.
16/990,602
Granted
Nov 18, 2025
Kind
B2
Abstract

Provided are methods, compositions, and systems for the detection of a target analyte. Also provided are methods, compositions, and systems for determining the concentration one or more target analytes in fluid solution. The compositions include nanopore conjugates in which a nanopore protein monomer is joined to a capture tag. Tethered to the nanopore protein conjugate is an analyte ligand directed to a specific analyte. When a voltage is applied across a nanopore assembly including the nanopore conjugate, the nanopore captures the capture tag at a given capture rate. In the presence of the analyte to the analyte ligand, however, the capture rate of the capture tag changes, thus permitting detection of the analyte by the nanopore assembly. Further, based on the capture rate associated with binding between the analyte and the analyte ligand, the concentration of the analyte can be determined using association/dissociation kinetics.

Claims (19)

1 . A nanopore protein conjugate comprising a nanopore protein monomer, an analyte attachment domain, and a capture tag, wherein (i) the capture tag comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 8, wherein (ii) the nanopore protein monomer of the nanopore protein conjugate comprises an amino acid sequence having at least 95% sequence identity to the sequence set forth as SEQ ID NO: 16 or SEQ ID NO: 6, and wherein (iii) the analyte attachment domain comprises an amino acid sequence that is located between the nanopore monomer and the capture tag.

2 . The nanopore protein conjugate of claim 1 , wherein the capture tag comprises an amino acid sequence having at least 98% sequence identity to the sequence set forth as SEQ ID NO: 8.

3 . The nanopore protein conjugate of claim 1 , wherein the nanopore protein monomer of the nanopore protein conjugate comprises an amino acid sequence having at least 98% sequence identity to the sequence set forth as SEQ ID NO: 16 or at least 98% sequence identity to the sequence set forth as SEQ ID NO: 6.

4 . The nanopore protein conjugate of claim 1 , wherein the nanopore protein conjugate comprises an amino acid sequence having at least 95% sequence identity to the sequence set forth as SEQ ID NO: 4 or SEQ ID NO: 7.

5 . An analyte detection complex, wherein the analyte detection complex comprises a nanopore protein conjugate of claim 1 and an analyte ligand that is joined to the nanopore protein conjugate, wherein the analyte ligand comprises a polypeptide sequence and wherein the analyte ligand is capable of binding a target analyte.

6 . The analyte detection complex of claim 5 , wherein the analyte ligand comprises an antibody or functional fragment thereof.

7 . The analyte detection complex of claim 5 , wherein the analyte ligand is joined to the nanopore protein conjugate via an isopeptide linkage.

8 . The analyte detection complex of claim 5 , wherein the analyte detection complex further comprises a linker member amino acid sequence and an attachment member amino acid sequence, wherein the linker member amino acid sequence attaches the analyte ligand to the attachment member amino acid sequence, wherein the attachment member amino acid sequence is joined to the nanopore protein complex at the analyte attachment domain of the nanopore protein conjugate, and wherein the linker member amino acid sequence and the attachment member amino acid sequence comprise a SpyCatcher/SpyTag binding pair of amino acid sequences, with the SpyTag sequence having at least 85% sequence identity to the amino acid sequence set forth as SEQ ID NO: 11.

9 . A nanopore assembly comprising at least one analyte detection complex of claim 5 .

10 . The nanopore assembly of claim 9 , wherein the nanopore assembly is a heptameric nanopore assembly and wherein each monomer of the heptameric nanopore assembly comprises an alpha-hemolysin monomer.

11 . A system for determining the concentration of analyte in a fluid solution, comprising:

a chip comprising a nanopore assembly, wherein the nanopore assembly is disposed within a membrane of the chip and wherein at least one nanopore protein monomer of the nanopore assembly comprises a capture tag and an analyte ligand, wherein the analyte ligand comprises a polypeptide sequence and wherein the analyte ligand is capable of binding a target analyte;

a sensing electrode positioned adjacent to or in proximity to the membrane, wherein the sensing electrode is configured to detect a signal from the nanopore assembly; and,

a computer processor, wherein the computer processor and sensing electrodes are configured to identify a first transition and a second transition associated with the nanopore assembly, the first transition corresponding to binding of the target analyte to the analyte ligand and the second transition corresponding to dissociation of the target analyte from the analyte ligand,

wherein the capture tag comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 8 and wherein the nanopore protein monomer comprises an amino acid sequence having at least 95% sequence identity to the sequence set forth as SEQ ID NO: 16 or SEQ ID NO: 6.

12 . The system of claim 11 , wherein a concentration of the target analyte in the fluid solution is determined based at least in part on the identified first transition and the identified second transition.

13 . The system of claim 11 , wherein the nanopore protein monomer is an alpha-hemolysin monomer.

14 . The system of claim 11 , wherein the nanopore protein conjugate comprises an amino acid sequence having at least 95% sequence identity to the sequence set forth as SEQ ID NO: 4 or SEQ ID NO: 7.

15 . The system of claim 11 , wherein the capture tag comprises an amino acid sequence having at least 98% sequence identity to the sequence set forth as SEQ ID NO: 8.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2020
From: CRAIG, TIMOTHY; AMBROSO, MARK; BAJAJ, KAPIL
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 053476/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2020
From: ROCHE SEQUENCING SOLUTIONS, INC.
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 053476/0171 →
Continuity (3)
Continuation PCTEP2019053482 · Feb 13, 2019
Provisional Application 62630993 · Feb 15, 2018
Related Publication 20210033591A1 · Feb 4, 2021
References Cited (18)
US 20200216887A1 · Craig · 2020 [cited by examiner]
WO 2001059453 · 2001 [cited by applicant]
WO WO2009033743A1 · 2009 [cited by examiner]
WO 2017042038 · 2017 [cited by applicant]
WO WO2017050722A1 · 2017 [cited by examiner]
WO 2017167811 · 2017 [cited by applicant]
Al Qaraghuli, Mohammed M et al. “Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response.” Scientific reports vol. 10,1 13696. Aug. 13, 2020… [cited by examiner]
Rabia, Lilia A et al. “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility.” Biochemical engineering journal vol. 137 (2018): 365-374. doi:10.1016/j.bej.2018.06.003 (… [cited by examiner]
Poosarla, Venkata Giridhar et al. “Computational de novo design of antibodies binding to a peptide with high affinity.” Biotechnology and bioengineering vol. 114,6 (2017): 1331-1342. doi:10.1002/bit.26244 (Year: 2017). [cited by examiner]
Lloyd, C et al. “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens.” Protein engineering, design & selection : PEDS vol. 22,3… [cited by examiner]
Khan, Tarique, and Dinakar M Salunke. “Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies.” Journal of immunology (Baltimore, Md. : 1950) vol. 192,11 (2014): 5398-405.… [cited by examiner]
Goel, Manisha et al. “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response.” Journal of immunology (Baltimore, Md. : 1950) vol. 173,12 (2004): 7358-67. doi: 10.40… [cited by examiner]
Edwards, Bryan M et al. “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS.” Journal of molecular biology vol. 334,1 (2003): 103-1… [cited by examiner]
Avinash, Kumar Thakur, et al., “Real-time measurement of protein-protein interactions at single-molecule resolution using a biological nanopre,” Nature Biotechnology, vol. 37, No. 1, Dec. 10, 2018, pp. 96-101. [cited by applicant]
Rotem, Dvir, et al., “Protein Detection by Nanopores Equipped with Aptamers.” Journal of the American Chemical Society, vol. 134, No. 5, Feb. 8, 2012, pp. 2781-2787. [cited by applicant]
Winters-Hilt, Stephen, “The [alpha]-Hemolysin nanpore transduction detector—single-molecule binding studies and immunological screening of antibodies and aptamers,” BMC Bioinformatics, BioMed Central, London, GB, vol. 8… [cited by applicant]
Avinash, Kumar Thakur, et al., “Real-time measurement of protein-protein interactions at single-molecule resolution using a biological nanopore,” Nature Biotechnology, vol. 37, No. 1, Dec. 10, 2018, pp. 96-101. [cited by applicant]
International Search Report and Written Opinion for PCT/EP2019/053482, mailed Apr. 18, 2019. [cited by applicant]